

## Patulosides A and B, Novel Xanthone Glycosides from Cell Suspension Cultures of *Hypericum patulum*

Kyoko Ishiguro,\* Rie Yamamoto, and Hisae Oku

School of Pharmaceutical Sciences, Mukogawa Women's University, Koshien Kyuban-cho, Nishinomiya, 663-8179, Japan

Received November 18, 1998

Two new xanthone glycosides, patuloside A (3- $\beta$ -D-glucopyranosyloxy-1,5,6-trihydroxy-9H-xanthone-9-one, **1**) and patuloside B [3-(2-O- $\alpha$ -L-rhamnopyranosyl- $\beta$ -D-glucopyranosyl)oxy-1,5,6-trihydroxy-9H-xanthone-9-one, **2**], have been isolated from cell suspension cultures of *Hypericum patulum*. Their structures were elucidated by spectral techniques.


Plants of the genus *Hypericum* have been used as traditional medicinal plants in various parts of the world.<sup>1</sup> Recently, antifungal,<sup>2</sup> antibiotic,<sup>3</sup> antiviral,<sup>4</sup> and anticancer<sup>5</sup> compounds were isolated from these species. *Hypericum patulum* Thunb. (Guttiferae) has been used in traditional Chinese herbal medicine for the treatment of hepatitis, bacterial diseases, and nasal hemorrhage.<sup>6</sup> Previously, as part of a continuing study of *Hypericum*,<sup>3</sup> we reported the isolation and structure determination of 14 prenylated xanthones and epicatechins from chloroform or methanol extracts of cell suspension cultures induced from flowers of *H. patulum*<sup>7–11</sup> and discussed the possible biosynthetic relationships among these xanthones.<sup>9,12</sup> Recently, Takamiya et al. isolated anthocyanins and procyanidins from tissue, cell suspension, and adventitious root cultures of *H. patulum*.<sup>13</sup>

Further investigation of the *n*-BuOH extract from cell suspension cultures of *H. patulum* has led to the isolation of two new xanthone glycosides named patulosides A (**1**) and B (**2**). We describe herein the isolation, characterization, and structure elucidation of these compounds. This is the first report on the isolation of 1,3,5,6-tetrahydroxyxanthone glycosides from cell suspension cultures of *H. patulum*.

Suspension cells of *H. patulum* maintained in Linsmaier–Skoog (LS) medium<sup>14</sup> containing 2,4-D and kinetin at 27 °C in the dark were harvested at 2–3-week intervals. The harvested cells were dried and extracted successively with CHCl<sub>3</sub> and MeOH. The MeOH extract was suspended in water and extracted with EtOAc and *n*-BuOH, in turn. The *n*-BuOH extract was subjected to polyamide and Si gel column chromatography followed by further purification using gel filtration over Sephadex LH-20, and recrystallization from MeOH led to the isolation of two new xanthone glycosides, patulosides A (**1**) and B (**2**).

Patuloside A (**1**) crystallized as pale yellow needles, mp 282 °C. FABMS showed a molecular ion at *m/z* 423 [M + H]<sup>+</sup>, and a HRMS measurement established a molecular formula of C<sub>19</sub>H<sub>18</sub>O<sub>11</sub>. The IR spectrum suggested the presence of phenolic hydroxyl groups and a conjugated carbonyl group from bands at 3320 cm<sup>-1</sup> and 1643 cm<sup>-1</sup>. The UV spectrum exhibited characteristic absorption bands<sup>15</sup> of a 1,3,5,6-tetraoxygenated xanthone at  $\lambda_{\max}$  256, 281, and 325 nm. Acid hydrolysis of **1** yielded an aglycon and a sugar. The aglycon was identified as 1,3,5,6-tetrahydroxyxanthone (**3**),<sup>16</sup> which has been isolated previously from

the same culture, by direct comparison with an authentic sample.<sup>11</sup> The sugar unit was determined to be glucose by TLC.



The <sup>1</sup>H NMR spectrum of **1** showed the presence of two characteristic pairs of *meta*-coupled aromatic protons ( $\delta$  6.40, 6.63) and *ortho*-coupled aromatic protons ( $\delta$  6.87, 7.50), a hydrogen-bonded hydroxyl proton ( $\delta$  13.25), an anomeric proton ( $\delta$  5.07), and other sugar protons in the range of  $\delta$  3.16–3.72 (Table 1). The lowfield shift of H-8 ( $\delta$  7.50), *ortho*-coupled with H-7, indicated that H-8 is located in an area deshielded by a carbonyl group. Thus, the two hydroxyl groups should be located at C-5 and C-6. The <sup>13</sup>C NMR spectrum of **1** showed signals for 19 carbons in the molecule, with there being six saccharide carbons, including an anomeric carbon at  $\delta$  99.8 and 13 carbons corresponding to a tetrahydroxyxanthone moiety, with a carbonyl carbon at  $\delta$  179.8 (C-9). The spectroscopic data of **1** indicated it to be a monoglucoside of 1,3,5,6-tetrahydroxyxanthone (**3**). All signal assignments in the <sup>1</sup>H and <sup>13</sup>C NMR spectra were confirmed with <sup>1</sup>H–<sup>1</sup>H COSY and <sup>1</sup>H–<sup>13</sup>C COSY 2D NMR techniques (Table 1).

Downfield shifts<sup>17</sup> of 0.24 and 0.23 ppm for H-2 ( $\delta$  6.40) and H-4 ( $\delta$  6.63), respectively, in the <sup>1</sup>H NMR spectrum and downfield shifts of 0.50 and 0.7 ppm for C-2 ( $\delta$  98.3) and C-4 ( $\delta$  94.5), respectively, in the <sup>13</sup>C NMR spectrum of **1**, compared with analogous data for **3**,<sup>16</sup> suggested the location of a glucose moiety at the 3-hydroxyl group. The configuration of the anomeric proton was determined as  $\alpha$  from the <sup>1</sup>H NMR ( $J = 7.3$  Hz) and <sup>13</sup>C NMR (Glc-1 at  $\delta$  99.8) data.<sup>18</sup> Thus, the structure of patuloside A was established as 3-O- $\beta$ -D-glucopyranosyl-1,5,6-trihydroxyxanthone (**1**).

Patuloside B (**2**) crystallized as pale yellow needles, mp 233 °C, and the molecular formula of C<sub>25</sub>H<sub>28</sub>O<sub>15</sub> was established by HRFABMS measurements. Positive-ion FABMS showed a [M + H]<sup>+</sup> ion at *m/z* 569. The IR spectrum suggested the presence of phenolic hydroxyl groups at 3200 cm<sup>-1</sup> and a conjugated carbonyl group at 1650 cm<sup>-1</sup>, while the UV spectrum exhibited maxima at 206, 251, 281, and 325 nm.

\* To whom correspondence should be addressed. Tel.: 0798-47-1212. Fax: 0798-41-2792. E-mail: ishiguro@mwu.mukogawa-u.ac.jp.

**Table 1.**  $^1\text{H}$ ,  $^{13}\text{C}$  NMR and HMBC Data for Patulosides A (**1**) and B (**2**)<sup>a</sup>

position	patuloside ( <b>1</b> )		patuloside ( <b>2</b> )		HMBC
	$^{13}\text{C}$	$^1\text{H}$ ( $J$ )	$^{13}\text{C}$	$^1\text{H}$ ( $J$ )	
1	162.4		162.5		
2	98.3	6.40 d (2.1)	98.1	6.38 d (2.5)	1, 4, 9a
3	163.6		163.3		
4	94.5	6.63 d (2.1)	94.3	6.62 d (2.5)	2, 3, 4a, 9a
4a	156.9		157.0		
4b	145.7		146.2		
5	132.6		132.6		
6	153.6		152.6		
7	113.5	6.87 d (8.5)	113.3	6.95 d (8.8)	5, 8a
8	116.1	7.50 d (8.5)	116.0	7.52 d (8.8)	4b, 6, 9
8a	112.2		112.9		
9	179.8		179.9		
9a	102.9		103.0		
1-OH		13.25 s		13.15 s	
glucose moiety					
1'	99.8	5.07 d (7.3)	97.6	5.26 d (7.3)	
2'	73.0	3.16–3.51 m	76.2	3.53 m	Glc-4
3'	76.2	3.16–3.51 m	76.9	3.49 m	Glc-2
4'	69.5	3.16–3.51 m	69.6	3.22 m	Glc-3
5'	77.0	3.16–3.51 m	77.1	3.49 m	
6'	60.6	3.72 dd (1.8, 11.6)	60.5	3.50 dd (5.4, 8.8) 3.73 d (5.4)	Glc-4
rhamnose moiety					
1''			100.4	5.15 d (1.5)	Glc-2, Rha-2, -3, -5
2''			70.4	3.71 dd (1.5, 3.4)	Rha-3, -4
3''			70.5	3.35 dd (3.4, 9.8)	Rha-4
4''			71.8	3.22 m	Rha-2, -3
5''			68.3	3.77 m	
6''			18.0	1.21 d (5.9)	Rha-4, -5

<sup>a</sup> Data were recorded in DMSO-*d*<sub>6</sub> at 500 Hz ( $^1\text{H}$ ) or 125 MHz ( $^{13}\text{C}$ ). Multiplicities and coupling constants are given in Hz.

The  $^1\text{H}$  and  $^{13}\text{C}$  NMR data of **2** (Table 1) were similar to those of patuloside A (**1**), but **2** had an additional rhamnose moiety. The  $^1\text{H}$  NMR spectrum of **2** showed the presence of signals corresponding to a 1,3,5,6-tetrahydroxyxanthone skeleton, and the sugar moieties included two anomeric protons at  $\delta$  5.15 ( $J = 1.47$  Hz, Rha) and  $\delta$  5.26 ( $J = 7.33$  Hz, Glc). The  $^{13}\text{C}$  NMR spectrum of **2** showed 25 signals, of which 12 were assigned to the saccharide protons and 13 to a tetrahydroxyxanthone moiety. The sugar proton resonances were assigned based on the  $^1\text{H}$ – $^1\text{H}$  COSY spectrum, and the  $^{13}\text{C}$  NMR data were assigned from the  $^{13}\text{C}$ – $^1\text{H}$  COSY spectrum. The NMR data of **2** (Table 1) indicated that it was a monorhamnoside of patuloside A (**1**). Partial acid hydrolysis of **2** with 10% formic acid yielded L-rhamnose and **1**, which was identified by comparison with an authentic sample.

The position of the rhamnose linkage in **2** was established at the 2'-hydroxyl group of the glucose moiety by HMBC techniques (Table 1), which showed cross peaks between the signals at  $\delta$  5.15 (Rha-1) and  $\delta$  76.2 (Glc-2). The configuration of anomeric protons of the glucose and rhamnose were determined as  $\alpha$  and  $\beta$  based on  $J$  values in the  $^1\text{H}$  NMR spectrum and chemical shifts in the  $^{13}\text{C}$  NMR spectrum.<sup>18</sup> Thus, the structure of patuloside B was established as 3-*O*-(2-*O*- $\alpha$ -L-rhamnopyranosyl)- $\beta$ -D-glucopyranosyl-1,5,6-trihydroxyxanthone (**2**).

Prenylated or glycosylated 1,3,6,7-tetrahydroxyxanthone derivatives and prenylated 1,3,5,6-tetrahydroxyxanthone derivatives have been isolated to date from cell suspension cultures of *H. patulum*. However, glycosylated 1,3,5,6-tetrahydroxyxanthone derivatives (**1** and **2**) are reported for the first time in this study. The co-occurrence of 1,3,5,6- and 1,3,6,7-tetraoxygenated xanthenes in species of the Guttiferae<sup>19</sup> and Moraceae<sup>20</sup> has been reported, and their coexistence in cell suspension cultures of *H. patulum* was shown for the first time by Ishiguro et al.<sup>9</sup>

In a previous study, we reported antimicrobial activity against *Staphylococcus aureus* and *Escherichia coli* of xanthone derivatives isolated from *H. patulum* cultures.<sup>12</sup> We considered it worth investigating the same biological effect for patulosides A (**1**) and B (**2**). However, these compounds did not suppress the growth of *S. aureus* and *E. coli* at 1 mg/mL using an agar-well method.<sup>18</sup> Therefore, this result supports our previous conclusion that the antibacterial activity of xanthone derivatives from *H. patulum* is dependent on the presence of either a prenyl group or a cyclopentane ring in the molecule.

## Experimental Section

**General Experimental Procedures.** Melting points were determined on a Yanagimoto micro melting-point apparatus. IR spectra were recorded on a Shimadzu 435 spectrometer and the UV absorption spectra with Hitachi 323 spectrometer.  $^1\text{H}$  and  $^{13}\text{C}$  NMR spectra were recorded with JEOL JNM-GSX 500 spectrometers (TMS as internal reference). FABMS were performed on a JEOL JMS-DX 303 double-focusing spectrometer, with an ion-accelerating voltage of 3 kV. A fast-atom xenon beam was generated from  $\text{Xe}^+$  ions that were accelerated to 6 kV. The mass maker was calibrated with poly(ethylene glycol)-400 for patuloside A (**1**) and poly(ethylene glycol)-600 for patuloside B (**2**) (resolution = 5000).

**Plant Material.** Seedlings of *H. patulum* were grown at Mukogawa Women's University and verified by Dr. G. Yoneda (Faculty of Pharmaceutical Sciences, Osaka University, Osaka, Japan). A voucher sample (MWU P3144014) is kept at Mukogawa Women's University.

**Suspension Culture.** Callus tissues were induced from the flower of *H. patulum* on LS solid medium containing 3% sucrose;  $10^{-5}$  M 2,4-D;  $10^{-7}$  M kinetin; and 1.4% agar (pH 5.5) in the dark at 27 °C. Callus tissue cultures were transferred into liquid LS medium<sup>14</sup> containing 3% glucose;  $10^{-5}$  M 2,4-D; and  $10^{-7}$  M kinetin (pH 5.5) to initiate suspension cultures and were subcultured every 2–3 weeks for one year. Suspen-

sion cultures were maintained at 27 °C in the dark on a rotary shaker (100 rpm).

**Extraction of Cultured Cells.** Cells were collected by filtering the suspension cultures at 2–3-week intervals. Whole cells (1.2 kg), after being washed with H<sub>2</sub>O and dried under a flow of hot air at 60 °C, were extracted successively with CHCl<sub>3</sub> and MeOH.

**Isolation of 1 and 2.** The MeOH extract (283 g) was dissolved in a minimal amount of H<sub>2</sub>O and partitioned with EtOAc. The aqueous phase was then extracted with *n*-BuOH. The *n*-BuOH extract (30 g) was subjected to polyamide column chromatography using H<sub>2</sub>O and MeOH as solvents. The MeOH-soluble eluent was subjected to Si gel column chromatography using CHCl<sub>3</sub>–MeOH as eluent. A fraction eluted by CHCl<sub>3</sub>–MeOH (5:1) was purified by gel filtration over Sephadex LH-20 with MeOH and was recrystallized from MeOH to obtain patuloside A (**1**, 3.8 mg). The CHCl<sub>3</sub>–MeOH (3:1) fraction was recrystallized from MeOH to obtain patuloside B (**2**, 23 mg).

**Patuloside A (1):** pale yellow needles (MeOH), mp 282 °C; UV (MeOH)  $\lambda_{\max}$  (log  $\epsilon$ ) 206 (4.20), 251 (4.52), 281 (3.89), 325 (4.14) nm; IR (KBr)  $\nu_{\max}$  3320 (br. OH), 2870, 1643, 1600, 1495, 1460 cm<sup>-1</sup>; <sup>1</sup>H NMR (DMSO-*d*<sub>6</sub>, 500 MHz) and <sup>13</sup>C NMR (DMSO-*d*<sub>6</sub>, 125 MHz), see Table 1; positive FABMS *m/z* 423 [M + 1]<sup>+</sup> (99); HRFABMS *m/z* 423.0934 (calcd for C<sub>19</sub>H<sub>18</sub>O<sub>11</sub>, 423.0927).

**Patuloside B (2):** pale yellow needles (MeOH), mp 233 °C; UV (MeOH)  $\lambda_{\max}$  (log  $\epsilon$ ) 205 (4.25), 251 (4.02), 281 (4.63), 325 (4.35) nm; IR (KBr)  $\nu_{\max}$  3400 (br. OH), 3200, 2850, 1650, 1590, 1610, 1490, 1460, 1400 cm<sup>-1</sup>; <sup>1</sup>H NMR (DMSO-*d*<sub>6</sub>, 500 MHz) and <sup>13</sup>C NMR (DMSO-*d*<sub>6</sub>, 125 MHz), see Table 1; positive FABMS *m/z* 569 [M + 1]<sup>+</sup> (99); HRFABMS *m/z* 569.1514, (calcd for C<sub>25</sub>H<sub>28</sub>O<sub>15</sub>, 569.1507).

**Antimicrobial Assay.** The in vitro antimicrobial activity was determined by the agar-well method<sup>21</sup> using both *Staphylococcus aureus* 209P JC-1 and *Escherichia coli* NIHJ JC-2. Plates were prepared with 4-mm deep sensitivity test agar medium (Eiken Chemical Co., Ltd., Tokyo, Japan), which had previously been inoculated with 1% (v/v) of a test organism grown overnight at 37 °C in heart infusion broth (Nissui Pharmaceutical Co., Ltd., Tokyo, Japan). Holes of 8-mm

diameter were bored in the medium with a sterile borer and filled with a 40- $\mu$ L solution (1 mg/mL) of each test sample. The plates were sealed and then incubated for 18 h at 37 °C. The activity was expressed as the diameter of the inhibition.

## References and Notes

- (1) Yazaki, K.; Okada, T. *Biotechnol. Agric. Forest.: Medicinal and Aromatic Plants VI*; Bajaj, Y. P. S., Ed.; Springer-Verlag: Berlin, 1994; Vol. 26, pp 167–178.
- (2) Rocha, L.; Marston, A.; Kaplan, M. A.; Stoeckli-Evans H.; Thull, U.; Testa, B.; Hostettmann, K. *Phytochemistry* **1994**, *36*, 1381–1385.
- (3) Ishiguro, K.; Nagata, S.; Fukumoto, H.; Yamaki, M.; Isoi, K. *Phytochemistry* **1994**, *35*, 469–471.
- (4) Diwu, Z. *Photochem. Photobiol.* **1995**, *61*, 529–539.
- (5) Renard, J. N.; Koike, N.; Kim, T.; Shimo, K.; Suzuta, T. *Anticancer Res.* **1985**, *5*, 594–597.
- (6) Chang Su New Medical College, *Dictionary of Chinese Crude Drugs*, Shanghai Scientific Technological Publishers: Shanghai, 1994.
- (7) Ishiguro, K.; Fukumoto, H.; Nakajima, M.; Isoi, K. *Phytochemistry* **1993**, *33*, 839–840.
- (8) Ishiguro, K.; Nakajima, M.; Fukumoto, H.; Isoi, K. *Phytochemistry* **1995**, *38*, 867–869.
- (9) Ishiguro, K.; Nakajima, M.; Fukumoto, H.; Isoi, K. *Phytochemistry* **1995**, *39*, 903–905.
- (10) Ishiguro, K.; Fukumoto, H.; Suitani, A.; Nakajima, M.; Isoi, K. *Phytochemistry* **1996**, *42*, 435–437.
- (11) Ishiguro, K.; Nagareya, N.; Suitani, A.; Fukumoto H. *Phytochemistry* **1997**, *44*, 1065–1066.
- (12) Ishiguro, K.; Oku, H.; Isoi, K. *Biotechnol. Agric. Forest.: Medicinal and Aromatic Plants XI*; Bajaj, Y. P. S., Ed.; Springer-Verlag: Berlin, 1999; Vol. 43; pp 199–212.
- (13) Takamiya, M.; Tanaka, N.; Touno, K.; Terahara, N.; Shimomura, K.; Ishimaru, K. *Jpn. J. Food Chem.* **1998**, *51*, 3–8.
- (14) Linsmaier, E. M.; Skoog, F. *Physiol. Plant.* **1965**, *18*, 100–127.
- (15) Chaudhuri, R. K.; Ghosal, S. *Phytochemistry* **1971**, *10*, 2425–2432.
- (16) (a) Abou-Shoer, M.; Suwanborirux, K.; Habib, A.-A. M.; Chang, C.-J.; Cassidy, J. M. *Phytochemistry* **1993**, *34*, 1413–1420. (b) Frahm, A. W.; Chaudhuri, R. K. *Tetrahedron* **1979**, *35*, 2035–2038.
- (17) Markham, K. R.; Ternai, B.; Stanley, R.; Geiger, H.; Mabry, T. J. *Tetrahedron* **1978**, *34*, 1389–1397.
- (18) Breitmaier, E.; Voelter, W. *Carbon-13 NMR Spectroscopy*; VCH: New York, 1987; pp 380–394.
- (19) Sultanbawa, M. U. S. *Tetrahedron* **1980**, *36*, 1465–1506.
- (20) Nomura, T.; Hano, Y. *Nat. Prod. Rep.* **1994**, *11*, 205–218.
- (21) Hartly, E.; Adamson, D. M. C. *British Pharmacopoea*, Appendix XIV; Her Majesty's Stationery Office: London, 1973; p A102.

NP980519X